{
  "cohort": "ER+/HER2- MBC, 2L, Site B, by Regimen (2024–2025)",
  "insight_type": "Site Regimen Variation",
  "summary": "At Site B, all CDK4/6 inhibitors are underutilized, with palbociclib at just 28%. Increasing utilization across regimens could yield $45,000/year.",
  "chart": {
    "type": "bar",
    "unit": "regimen",
    "data": [
      { "name": "Palbociclib", "value": 28, "gap": -37, "highlight": true },
      { "name": "Abemaciclib", "value": 32, "gap": -33, "highlight": false },
      { "name": "Ribociclib", "value": 45, "gap": -20, "highlight": false }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "financial_impact": {
    "annual_opportunity": "$45,000/year",
    "math": "$45,000/year = 12 patients × $3,750 margin per patient"
  },
  "clinical_impact": {
    "description": "Improving CDK4/6i utilization at Site B increases survival.",
    "quantitative": "+9.2 months PFS"
  },
  "peer_comparison": {
    "description": "Overall peer average is 65%.",
    "peer_benchmark": 65
  },
  "weighted_score": 78,
  "action_steps": [
    "Provide targeted education to Site B clinicians",
    "Review Site B's workflow for CDK4/6i eligibility",
    "Implement Site B-specific CDK4/6i clinical pathway"
  ],
  "suggestions": [
    "Share best practices from other sites with Site B"
  ],
  "drilldowns": [
    {
      "label": "By Provider",
      "cohort": "ER+/HER2- MBC, 2L, Site B, by Provider",
      "jsonFile": "breast-cancer-cdk46-siteb-by-provider.json",
      "drilldownLevel": 3
    }
  ]
} 